American Journal of Cancer Research | |
Therapy of adrenocortical cancer: present and future | |
Daniela F Maluf1  | |
关键词: Adrenocortical carcinoma; targeted therapy; review; mitotane; radiotherapy; chemotherapy; β; -catenin; Steroidogenic factor 1 (SF-1) inverse; mTOR; antagonists; | |
DOI : | |
学科分类:肿瘤学 | |
来源: e-Century Publishing Corporation | |
【 摘 要 】
Adrenocortical carcinoma is a rare endocrine malignancy with an estimated worldwide incidence of 0.5 - 2 per million/year. This neoplasm is characterized by a high risk of recurrence and a dismal prognosis owing to unsatisfactory overall survival. Surgery represents the cornerstone of adrenocortical carcinoma therapy, which can be associated to radiotherapy and adjuvant mitotane administration. In advanced cases, different chemotherapy regimens are used, but their relative efficacy is still unknown until the results of clinical trials under way will be published. Novel drugs have been recently developed based on the discovery of molecular pathways that trigger development and evolution of these tumors. More efficient treatments are widely expected in the future from these new targeted therapies as a hope of cure for patients affected with this aggressive malignancy.
【 授权许可】
CC BY-NC
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201904037212633ZK.pdf | 247KB | download |